SUBSCRIBE
SUBSCRIBE
BioForest

SCOLR Pharma, Inc. Reports Promising Results From Second CDT(R)-Raloxifene Trial

October 25, 2006 | 
1 min read

BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX : DDD) announced today promising results from its recently completed CDT®-raloxifene bioavailability testing in Canada.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: 3D rendering of antibody-drug conjugate/
BioForest
ADC-Focused ProfoundBio Raises $112M in Oversubscribed Series B
February 14, 2024
 · 
2 min read
 · 
Tyler Patchen
A moving truck parked in San Francisco’s Nob Hill
BioForest
How the Pandemic Shifted the Rules of Recruiting
October 25, 2023
 · 
4 min read
 · 
Amanda Heidt
2023 Hotbed Maps
Bio NC
BioSpace Releases Exclusive Hotbed Maps
January 5, 2023
 · 
4 min read
 · 
Lisa Munger